Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J 4Q Revenues up 7% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

J&J 4Q Revenues up 7%

Growth driven by DARZALEX, ERLEADA, TECVAYLI, CARVYKTI, STELARA, TREMFYA, and SPRAVATO.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
4Q Revenues: $21.4 billion (+7%)
4Q Earnings: $4.1 billion (+28%)
FY Revenues: $85.2 billion (+6.5)
FY Earnings: $13.3 billion (-18.6%)
Comments: Innovative Medicine worldwide operational sales grew 5% in the quarter. Growth was driven by DARZALEX (daratumumab) with sales up 22% to $2.6 billion, ERLEADA (apalutamide) with sales up 20% to $647 million, TECVAYLI (teclistamab-cqyv) in Other Oncology, and CARVYKTI (ciltacabtagene autoleucel) with sales of $159 million. STELARA (ustekinumab) sales were $2.75 million, up 15%. TREMFYA (guselkumab) sales were $910 million, up 21%. SPRAVATO (esketamine) sales were $206 million, up 74%. Growth was partially offset by ZYTIGA (abiraterone acetate) with sales down 26% to $201 million, and IMBRUVICA (ibrutinib) with sales down 9% to $788 million, and REMICADE (infliximab) sales down 10% to $429 million. COVID-19 Vaccine sales were down 94% to $44 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters